证券代码：002737 证券简称：葵花药业 公告编号：2025-061 葵花药业集团股份有限公司 关于修改公司《章程》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）于 2025 年 10 月 10 日召开公司第五届董事会第十一次会议，审议通过《关于修改公司章程 的议案》。为进一步规范公司运作，维护公司及全体股东的合法权益，根据《公 司法》、《证券法》、《深圳证券交易所股票上市规则》、《上市公司章程指引》、 《上市公司自律监管指引第 1 号——主板上市公司规范运作》、《上市公司独立 董事管理办法》等有关规定，对公司《章程》内容进行了修改，具体情况如下： | 修订前 | 修订后 | | --- | --- | | 第一条为维护公司、股东和债权人的合 | 第一条为维护公司、股东、职工和债权 | | 法权益，规范公司的组织和行为，根据《中 | 人的合法权益，规范公司的组织和行为，根据 | | 华人民共和国公司法》（以下简称"《公司 | 《中华人民共和国公司法》（以下简称"《公 | | 法》"）、《中华人 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-062 葵花药业集团股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东大会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市 规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法 律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 10 月 27 日 13:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 10 月 27 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投 票的具体时间为 2025 年 10 月 27 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-059 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第十一次会议于 2025 年 10 月 10 日上午 9 时 30 分以通讯方式召开。会议由公 司董事长关玉秀女士召集，会议通知及议案于 2025 年 9 月 26 日通过电子邮件形 式发出。会议应参加表决董事 9 人，实际参加表决董事 9 人。 本次会议召集、召开程序符合《公司法》及相关法律法规以及《公司章程》 之规定，会议决议合法有效。 二、董事会会议审议情况 1、审议通过《关于授权葵花集团及其下属企业使用公司部分注册商标暨关 联交易的议案》 《关于授权控股股东及下属企业使用公司部分注册商标暨关联交易的公告》 披露于本公司指定信息披露媒体《证券日报》、《上海证券报》、巨潮资讯网 （http://www.cninfo.com.cn）。 同意授权控股股东葵花集团有限公司（含其合并报表范围内子公司）使用公 司第 456 ...

证券日报网讯葵花药业9月25日在互动平台回答投资者提问时表示，公司目前产品以中成药为主，未来 将通过"买、改、联、研"等多维渠道扩大产品覆盖，完善品类布局。 （文章来源：证券日报） ...

Core Insights - The Chinese health food industry is experiencing a structural transformation characterized by "inventory reshuffling and weakened growth," moving away from the era of broad-based growth due to regulatory upgrades and evolving consumer concepts [2][10] Industry Overview - In the first half of 2025, the online market for health food reached a sales figure of 60.41 billion yuan, with a year-on-year growth rate of 16.2%, indicating the sector's competitive intensity [2] - Major companies are facing declining revenues, with inventory turnover days increasing, signaling a challenging environment for traditional growth models [2][10] Company Performance - The vitality ranking of health food companies shows significant performance disparities, with innovative companies gaining a premium [4][5] - Key players like健合集团 reported a revenue of 7.02 billion yuan, with a 71.7% increase in revenue from emerging Asian markets, highlighting successful global strategies [5] - 仙乐健康, a leading CDMO, achieved a revenue of 2.042 billion yuan (+2.57%), with a remarkable 200% growth in private traffic contributing to its success [7] - 汤臣倍健's second-quarter net profit grew by 71.4%, indicating effective inventory management and operational efficiency [9] Market Trends - The health food sector is witnessing structural growth, with significant differentiation in performance across companies and product categories [5] - Categories such as cardiovascular health (37.4% growth), bone health (34.9% growth), and women's health (26.0% growth) are emerging as key growth drivers [10] - The shift towards new consumption channels, including live streaming and private domains, is becoming crucial for enhancing customer loyalty and combating rising public traffic costs [10][13] Future Outlook - The industry is expected to continue its trend of differentiation, with a focus on precision, technology, and globalization as core competitive strategies [10][12] - Companies are encouraged to explore overseas markets, particularly in Southeast Asia and Latin America, to leverage demographic advantages and growth potential [13] - The competition is entering a new phase centered on quality improvement, with long-term strategic focus and technological accumulation being vital for success [13]

证券代码：002737 证券简称：葵花药业 公告编号：2025-058 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经葵花药业集团股份有限公司（以下简称"公司"）第五届董事会第六次会 议、第五届监事会第四次会议、公司 2024 年年度股东大会审议通过，公司决定 使用闲置自有资金额度不超过 20 亿元人民币进行现金管理，上述额度自股东大 会审议通过之日起 12 个月内有效，有效期内，上述额度可滚存使用。 授权董事长在上述期限和额度内，行使本次现金管理的决策权并签署相关法 律文件，由公司财务部门负责具体实施。 有关上述具体内容详见《上海证券报》、《证券日报》、巨潮资讯网 （http:www.cninfo.com.cn）公司公告。 一、本次进行现金管理的实施进展情况 根据上述决议，公司于近日使用闲置自有资金 140,000 万元购买了部分理财 产品，具体情况如下： | 4 | 中国银行 哈尔滨香 | （机构专属）中银理 财-睿享（封闭式） | 固定收益类 非保本浮动 | 60,000.00 | ...

Group 1 - The core point of the article is that Kewang Pharmaceutical (002737) reported a total of 55,000 shareholders as of the end of August [1]

Group 1 - The company has received the drug registration certificate for Desloratadine Oral Suspension from the National Medical Products Administration, indicating compliance with drug registration requirements [1][4] - The drug is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children aged 2 and above, and chronic idiopathic urticaria in children aged 6 months and above [2][3] - The product is classified as a prescription drug and falls under the category of Class 3 chemical drugs, with a specification of 120ml containing 0.72g of the active ingredient Desloratadine [6][4] Group 2 - The approval of Desloratadine Oral Suspension will help the company expand its product pipeline and enhance its therapeutic area coverage [4] - The company plans to strengthen quality and process control during the product's subsequent mass production and market launch [4] - The drug registration number for Desloratadine is H20255183, and the manufacturing entity is Chongqing Little Sunflower Children's Pharmaceutical Co., Ltd., a subsidiary of the company [6][4]

Group 1 - The core point of the article is that Kew Flower Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for its oral suspension of Fexofenadine Hydrochloride [2] Group 2 - The approval of the drug registration indicates a significant milestone for the company in expanding its product portfolio [2] - This development may enhance the company's market position in the pharmaceutical industry, particularly in allergy treatment [2] - The registration could lead to increased revenue opportunities for Kew Flower Pharmaceutical as it introduces the new product to the market [2]

Core Viewpoint - The approval of the oral suspension of Fexofenadine Hydrochloride by the National Medical Products Administration will enhance the company's product pipeline and therapeutic coverage in the allergy treatment sector [1] Group 1 - The company has received a drug registration certificate for Fexofenadine Hydrochloride oral suspension [1] - This product is aimed at the allergy treatment market, indicating a strategic expansion in the company's offerings [1] - The company plans to accelerate the mass production and market launch of this product, facilitating the rapid conversion of research outcomes into marketable products [1]